Implementation of Calcium and Vitamin D Supplementation in Glucocorticosteroid-Induced Osteoporosis Prevention Guidelines-Insights from Rheumatologists

Overview

Journal Rambam Maimonides Med J

Specialty General Medicine

Date 2023 Apr 28

PMID 37116065

Authors

Tal Gazitt

Joy Feld

Devy Zisman

Affiliations

Soon will be listed here.

Abstract

Glucocorticosteroid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis but is underdiagnosed and undertreated. Our aim in this communication is to review the literature on the implementation of current GIO prevention practices such as calcium and vitamin D supplementation with emphasis on the rheumatologists' perspective relating to the need for development of novel GIO educational prevention measures.

Citing Articles

Association between systemic lupus erythematosus and osteoporosis: a mendelian randomization analysis.

Xu D, Wu B BMC Rheumatol. 2024; 8(1):17.

PMID: 38711124 PMC: 11071324. DOI: 10.1186/s41927-024-00388-5.

References

Rajkomar A, Dean J, Kohane I . Machine Learning in Medicine. N Engl J Med. 2019; 380(14):1347-1358. DOI: 10.1056/NEJMra1814259. View

van Staa T, Leufkens H, Cooper C . The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13(10):777-87. DOI: 10.1007/s001980200108. View

Massafra U, Migliaccio S, Bancheri C, Chiacchiararelli F, Fantini F, Leoni F . Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study. J Endocrinol Invest. 2012; 36(2):92-6. DOI: 10.3275/8288. View

Iki M, Fujimori K, Nakatoh S, Tamaki J, Ishii S, Okimoto N . Guideline adherence by physicians for management of glucocorticoid-induced osteoporosis in Japan: a nationwide health insurance claims database study. Osteoporos Int. 2022; 33(5):1097-1108. DOI: 10.1007/s00198-021-06265-y. View

Guzman-Clark J, Fang M, Sehl M, Traylor L, Hahn T . Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Rheum. 2007; 57(1):140-6. DOI: 10.1002/art.22462. View

Solomon D, Katz J, La Tourette A, Coblyn J . Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum. 2004; 51(3):383-7. DOI: 10.1002/art.20403. View

Yood R, Harrold L, Fish L, Cernieux J, Emani S, Conboy E . Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med. 2001; 161(10):1322-7. DOI: 10.1001/archinte.161.10.1322. View

LeBoff M, Chou S, Ratliff K, Cook N, Khurana B, Kim E . Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. N Engl J Med. 2022; 387(4):299-309. PMC: 9716639. DOI: 10.1056/NEJMoa2202106. View

Gazitt T, Elias M, Feld J, Lavi I, Haddad A, Bishara-Garzuzi R . Implementation of recommendations for prevention of glucocorticosteroid-induced osteoporosis in hospitalized patients. Clin Rheumatol. 2021; 40(10):4361-4363. DOI: 10.1007/s10067-021-05820-6. View

10.

Brennan-Olsen S, Hosking S, Dobbins A, Pasco J . Translating Osteoporosis Prevention Guidelines. J Aging Health. 2016; 29(3):531-545. DOI: 10.1177/0898264316641076. View

11.

LeBoff M, Murata E, Cook N, Cawthon P, Chou S, Kotler G . VITamin D and OmegA-3 TriaL (VITAL): Effects of Vitamin D Supplements on Risk of Falls in the US Population. J Clin Endocrinol Metab. 2020; 105(9). PMC: 7365686. DOI: 10.1210/clinem/dgaa311. View

12.

Lems W, Dreinhofer K, Bischoff-Ferrari H, Blauth M, Czerwinski E, da Silva J . EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann Rheum Dis. 2016; 76(5):802-810. DOI: 10.1136/annrheumdis-2016-210289. View

13.

Weinstein R . Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011; 365(1):62-70. DOI: 10.1056/NEJMcp1012926. View

14.

Carter M . Prevention of Glucocorticoid-Induced Osteoporosis: Clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting. J Clin Densitom. 2018; 22(1):25-30. DOI: 10.1016/j.jocd.2018.03.009. View

15.

Hahn J, Cook N, Alexander E, Friedman S, Walter J, Bubes V . Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022; 376:e066452. PMC: 8791065. DOI: 10.1136/bmj-2021-066452. View

16.

Compston J . Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018; 61(1):7-16. PMC: 5997116. DOI: 10.1007/s12020-018-1588-2. View

17.

Aagaard E, Lin P, Modin G, Lane N . Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital. Am J Med. 1999; 107(5):456-60. DOI: 10.1016/s0002-9343(99)00265-x. View

18.

Curtis J, Westfall A, Allison J, Becker A, Casebeer L, Freeman A . Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum. 2005; 52(8):2485-94. DOI: 10.1002/art.21194. View

19.

Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N . UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017; 12(1):43. PMC: 5397452. DOI: 10.1007/s11657-017-0324-5. View

20.

Blalock S, Norton L, Patel R, Dooley M . Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 2005; 53(5):732-9. DOI: 10.1002/art.21446. View